Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone

Inclusion criteria

• Subjects under a stable condition after Post-Percutaneous Coronary Artery Intervention over three months
• 20~86 years old
• Willing to adhere to protocol requirements and sign a informed consent form

Exclusion criteria

• Subject who did not undergo or failed Drug-Stent Implantation
• Subjects who took an anti-coagulant, anti-thrombotic regularlly( ≥ 2weeks in a month) before the study, or plan to have continuous treatment during the study(Except Aspirin alone or combination of Aspirin and Clopidogrel)
• Subjects with a history of substance or alchol abuse
• Subjects with a history of hypersensitivity to Clopidogrel, Aspirin or other NSAIDS
• Subjects having Aspirin or other NSAIDs-induced Asthma or history
• Subjects with Severe hepatopathy(AST and ALT > 5 times the upper limit of normal)
• Subjects with Severe nephropathy(Cr > 3 times the upper limit of normal)
• Subjects with hemorrhage like gastric ulcer, intracranial hemorrhage etc.
• Subjects with high risk of hemorrhage like blood coagulation disorders, uncontrolled severe hypertension, active bleeding, history of severe bleeding
• subjects who are pregnant, breastfeeding
• Subjects not using medically acceptable birth control
• Subjects who are unsuitable to take the Investigational product due to a medical/mental condition
• Subjects inherently having Galactose malobsorption, Lactase deficiency or Glucose-Galactose malobsorption